188 related articles for article (PubMed ID: 35671305)
1. Mitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma.
Gu YR; Kim J; Na JC; Han WK
PLoS One; 2022; 17(6):e0269432. PubMed ID: 35671305
[TBL] [Abstract][Full Text] [Related]
2. SIRT3 Overexpression Inhibits Growth of Kidney Tumor Cells and Enhances Mitochondrial Biogenesis.
Liu H; Li S; Liu X; Chen Y; Deng H
J Proteome Res; 2018 Sep; 17(9):3143-3152. PubMed ID: 30095923
[TBL] [Abstract][Full Text] [Related]
3. HSP60 silencing promotes Warburg-like phenotypes and switches the mitochondrial function from ATP production to biosynthesis in ccRCC cells.
Teng R; Liu Z; Tang H; Zhang W; Chen Y; Xu R; Chen L; Song J; Liu X; Deng H
Redox Biol; 2019 Jun; 24():101218. PubMed ID: 31112866
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial Sirt3 supports cell proliferation by regulating glutamine-dependent oxidation in renal cell carcinoma.
Choi J; Koh E; Lee YS; Lee HW; Kang HG; Yoon YE; Han WK; Choi KH; Kim KS
Biochem Biophys Res Commun; 2016 Jun; 474(3):547-553. PubMed ID: 27114304
[TBL] [Abstract][Full Text] [Related]
5. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
Reustle A; Menig LS; Leuthold P; Hofmann U; Stühler V; Schmees C; Becker M; Haag M; Klumpp V; Winter S; Büttner FA; Rausch S; Hennenlotter J; Fend F; Scharpf M; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Clin Transl Med; 2022 Jun; 12(6):e883. PubMed ID: 35678045
[TBL] [Abstract][Full Text] [Related]
6. Sirtuin 3 is required for the protective effect of Resveratrol on Manganese-induced disruption of mitochondrial biogenesis in primary cultured neurons.
Sun Q; Kang RR; Chen KG; Liu K; Ma Z; Liu C; Deng Y; Liu W; Xu B
J Neurochem; 2021 Jan; 156(1):121-135. PubMed ID: 32426865
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma models.
Rupert C; Dell' Aversana C; Mosca L; Montanaro V; Arcaniolo D; De Sio M; Bilancio A; Altucci L; Palinski W; Pili R; de Nigris F
J Exp Clin Cancer Res; 2023 May; 42(1):134. PubMed ID: 37231503
[TBL] [Abstract][Full Text] [Related]
9. Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial dysfunction.
Wang R; Liu Y; Mi X; Chen Q; Jiang P; Hou J; Lin Y; Li S; Ji B; Fang Y
Arch Biochem Biophys; 2020 Aug; 689():108415. PubMed ID: 32562663
[TBL] [Abstract][Full Text] [Related]
10. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
[TBL] [Abstract][Full Text] [Related]
11. SIRT3 affects mitochondrial metabolic reprogramming via the AMPK-PGC-1α axis in the development of benign prostatic hyperplasia.
Li Y; Wang Q; Li J; Shi B; Liu Y; Wang P
Prostate; 2021 Nov; 81(15):1135-1148. PubMed ID: 34411320
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic acid reverses Temsirolimus-induced changes in lipid droplets and mitochondrial networks in renal cancer cells.
Chhabra R; Nanjundan M
PLoS One; 2020; 15(6):e0233887. PubMed ID: 32492043
[TBL] [Abstract][Full Text] [Related]
13. Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury.
Morigi M; Perico L; Rota C; Longaretti L; Conti S; Rottoli D; Novelli R; Remuzzi G; Benigni A
J Clin Invest; 2015 Feb; 125(2):715-26. PubMed ID: 25607838
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol rescues cadmium-induced mitochondrial injury by enhancing transcriptional regulation of PGC-1α and SOD2 via the Sirt3/FoxO3a pathway in TCMK-1 cells.
Fu B; Zhao J; Peng W; Wu H; Zhang Y
Biochem Biophys Res Commun; 2017 Apr; 486(1):198-204. PubMed ID: 28286268
[TBL] [Abstract][Full Text] [Related]
15. SIRT3 and SIRT4 double-genes remodeled the mitochondrial network to induce hepatocellular carcinoma cell line differentiation and suppress malignant phenotypes.
Zhang L; Dai Z; Shi S; Yan Z; Yang J; Xue W; He Y; Mi S; Cheng C; Wang L; Li N; Tan W; Jiang Z; Sun H; Li S
Biochem Pharmacol; 2024 May; 223():116168. PubMed ID: 38548246
[TBL] [Abstract][Full Text] [Related]
16. Sirt3 modulates fatty acid oxidation and attenuates cisplatin-induced AKI in mice.
Li M; Li CM; Ye ZC; Huang J; Li Y; Lai W; Peng H; Lou TQ
J Cell Mol Med; 2020 May; 24(9):5109-5121. PubMed ID: 32281286
[TBL] [Abstract][Full Text] [Related]
17. Various forms of HIF-1α protein characterize the clear cell renal cell carcinoma cell lines.
Swiatek M; Jancewicz I; Kluebsoongnoen J; Zub R; Maassen A; Kubala S; Udomkit A; Siedlecki JA; Sarnowski TJ; Sarnowska E
IUBMB Life; 2020 Jun; 72(6):1220-1232. PubMed ID: 32250548
[TBL] [Abstract][Full Text] [Related]
18. The platelet isoform of phosphofructokinase contributes to metabolic reprogramming and maintains cell proliferation in clear cell renal cell carcinoma.
Wang J; Zhang P; Zhong J; Tan M; Ge J; Tao L; Li Y; Zhu Y; Wu L; Qiu J; Tong X
Oncotarget; 2016 May; 7(19):27142-57. PubMed ID: 27049827
[TBL] [Abstract][Full Text] [Related]
19. Receptor-interacting Protein 140 represses Sirtuin 3 to facilitate hypertrophy, mitochondrial dysfunction and energy metabolic dysfunction in cardiomyocytes.
You J; Yue Z; Chen S; Chen Y; Lu X; Zhang X; Shen P; Li J; Han Q; Li Z; Liu P
Acta Physiol (Oxf); 2017 May; 220(1):58-71. PubMed ID: 27614093
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Yan L; Ding B; Liu H; Zhang Y; Zeng J; Hu J; Yao W; Yu G; An R; Chen Z; Ye Z; Xing J; Xiao K; Wu L; Xu H
Theranostics; 2019; 9(26):8377-8391. PubMed ID: 31754403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
